Evaluating the impact of antiviral post-exposure prophylaxis for health-care workers during ebolavirus outbreaks: a modelling study
Authors:
- Jacob N. StapleyJSJacob N. Stapley
- Youngsuk KoYKYoungsuk Ko
- Geetha JeyapragasanGJGeetha Jeyapragasan
- Elana M.G. ChanECElana M.G. Chan
- Abel W. WalekhwaAWAbel W. Walekhwa
- Cathal MillsCMCathal Mills
- Christophe FraserCFChristophe Fraser
- Dav EbengoDEDav Ebengo
- Christl A. DonnellyCDChristl A. Donnelly
- Charles WhittakerCWCharles Whittaker
Preprint
Abstract
Background: Ebolavirus outbreaks place health-care workers (HCWs) at substantial risk, and HCW illness or death can weaken response capacity. The 2026 Bundibugyo virus disease outbreak in the DRC highlights the need for deployable countermeasures where species-specific vaccines are unavailable. With candidate antivirals under evaluation, but limited evidence on how best to use them if they become available, we assessed HCW-targeted antiviral post-exposure prophylaxis (PEP) across deployment and disruption scenarios. Methods: We developed a stochastic branching-process model of ebolavirus transmission, representing health-care, community, and funeral transmission, time-varying non-pharmaceutical interventions and HCW-targeted PEP. Calibrated to previous outbreaks (a high-burden “West Africa-like” scenario and a “DRC-like” scenario with conflict-disrupted response) we estimated HCW deaths and capacity loss averted by PEP, varying antiviral efficacy, coverage, deployment readiness, dosing delay, disruption, and allocation policy. Findings: At 80% efficacy and 80% coverage, PEP averted approximately 64% of HCW deaths across both archetypes. Under low readiness, where clinical evaluation and access expansion occurred during the outbreak and coverage reached only 50% over one year, reductions fell to 19% and 22% in the West Africa-like and DRC-like archetypes. In disruption scenarios, delayed dose receipt reduced HCW deaths averted from 83% to 50%; combined dosing delay and coverage loss retained only 35% of achievable impact. Dose efficiency varied by allocation: targeting recognised highest-risk exposures required 44 doses per HCW death averted, compared with 109 under broad allocation. Interpretation: HCW-targeted antiviral PEP could reduce occupational mortality and preserve clinical capacity during ebolavirus epidemics where vaccines are unavailable, but realising this benefit depends on implementation readiness, rapid delivery, operational coverage and efficient allocation. Funding: Gilead Sciences; UK NIHR; Oxford Martin School; Miller Institute; EDCTP; CEPIKeywords
Funding Information
- Oxford Martin School
- the Miller Institute for Basic Research in Science
- EDCTP3 (101145709)
This publication has 22 references indexed in Scilit:
- Quantifying the impact of a broadly protective sarbecovirus vaccine in a future SARS-X pandemicNature Communications, 2025
- Effect of a safe and dignified burial intervention on Ebola virus transmission in the eastern Democratic Republic of the Congo, 2018–19: a propensity score analysisThe Lancet Global Health, 2025
- Efficacy and safety of obeldesivir in low-risk, non-hospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled studyThe Lancet Infectious Diseases, 2025
- Oral obeldesivir provides postexposure protection against Marburg virus in nonhuman primatesNature Medicine, 2025
- Institutional trust and misinformation in the response to the 2018–19 Ebola outbreak in North Kivu, DR Congo: a population-based surveyThe Lancet Infectious Diseases, 2019
- Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapiesThe Lancet Infectious Diseases, 2018
- Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)The Lancet, 2017
- Health-care worker mortality and the legacy of the Ebola epidemicThe Lancet Global Health, 2015
- Chains of transmission and control of Ebola virus disease in Conakry, Guinea, in 2014: an observational studyThe Lancet Infectious Diseases, 2015
- Understanding the dynamics of Ebola epidemicsEpidemiology and Infection, 2006